Isabella Claudia Glitza

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.

Rodabe N. Amaria, Michael A. Postow, Michael T. Tetzlaff et al. · Journal of Clinical Oncology · 2021 · 44 citations

Medicine, Immunology, Oncology +17

Plasma Cell Enrichment Enhances Detection of High-Risk Cytogenomic Abnormalities by Fluorescence In Situ Hybridization and Improves Risk Stratification of Patients With Plasma Cell Neoplasms

Gary Lu, Ramya Muddasani, Robert Z. Orlowski et al. · Archives of Pathology & Laboratory Medicine · 2013 · 34 citations

Medicine, Hematology, Pathology +16

Association of the diversity and composition of the gut microbiome with responses and survival (PFS) in metastatic melanoma (MM) patients (pts) on anti-PD-1 therapy.

Jennifer A. Wargo, Vancheswaran Gopalakrishnan, Christine N. Spencer et al. · Journal of Clinical Oncology · 2017 · 33 citations

Life Sciences, Immunology, Microbiology +17

Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).

Isabella Claudia Glitza, Suzanne Phillips, Courtney Brown et al. · Journal of Clinical Oncology · 2020 · 27 citations

Medicine, Oncology, Pharmacology +17

OBX-115, an interleukin 2 (IL2)-sparing engineered tumor-infiltrating lymphocyte (TIL) cell therapy, in patients (pts) with immune checkpoint inhibitor (ICI)-resistant unresectable or metastatic melanoma.

Rodabe N. Amaria, Jennifer L. McQuade, Michael A. Davies et al. · Journal of Clinical Oncology · 2024 · 27 citations

Life Sciences, Immunology, Oncology +17